Effects of anthraglycoside B on EBV latency Ⅲ human Burkitt’s lymphoma cells

• Main Authors: Ya-Yun Cheng, 鄭雅勻
• Other Authors: Tsuey-Pin Lin
• Format: Others
• Language: zh-TW
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/68723731241292878814

碩士 === 嘉南藥理科技大學 === 保健營養系 === 101 === Epstein-Barr virus (EBV) is a γ - herpesvirus that infects 90% of the adult human population. EBV infects lymphocyte and epitheial cells which leads to Burkitt’s lymphoma (BL) and Hodgkin’s lymphoma (HL) and nasopharyngeal carcinoma (NPC). Our earlier studies showed that the ethyl acetate subfraction F2a from Polygonum cuspidatum induces a high level of reactive oxygen species (ROS) and increase the expression of the EBV latent membrane protein 1 (LMP1), EBNA1 and lytic proteins which causes apoptosis of B95-8 cells. The purpose of this study is to investigate whether the subfraction F2a of ethyl acetate from Polygonum cuspidatum root induces apoptosis of EBV latency Ⅲ Burkitt's lymphoma (Raji cells) via a reactive oxygen species (ROS) mechanism. Results show that F2a kills Raji cells, at a CC50 values of 10.8 ug/ml. F2a although does not induce ROS production and EBV lytic cycle, F2a promots the expression of LMP1, reducing intracellular phospho-IkBa/ IkBa expression, which lead to a increased caspase 3 activity and cleavage of PARP to trigger apoptosis of Raji cells. Therefore, F2a can be developed as a therapeutic drug in the treatment of Epstein-Barr virus-related tumors.